ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Has Consensus Price Target of $7.60 According to Analysts

Key Points

• Analyst sentiment is moderately bullish: Eight brokerages give ProQR Therapeutics a consensus “Moderate Buy” rating, with six buys, one hold and one sell. The average 12-month price target is $7.60.
• The stock has fallen sharply: PRQR opened at $1.31, near its 52-week low of $1.30, versus a 52-week high of $3.10. Its market capitalization is approximately $138 million.
• Recent quarterly results exceeded expectations: ProQR reported a quarterly loss of $0.09 per share versus the consensus estimate of a $0.13 loss, while revenue reached $10 million compared with analyst expectations of $4.56 million.

ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $7.60.

Several research firms have commented on PRQR. Chardan Capital restated a "buy" rating and issued a $3.00 price target on shares of ProQR Therapeutics in a report on Thursday, October 1st. HC Wainwright dropped their price objective on shares of ProQR Therapeutics to $8.00 and set a "buy" rating for the company in a research note on Thursday, October 1st. Wall Street Zen raised shares of ProQR Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 15th. Weiss Ratings upgraded shares of ProQR Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 14th. Finally, Bank of America began coverage on shares of ProQR Therapeutics in a report on Thursday, August 20th. They set a "buy" rating and a $8.00 price objective on the stock.

Hedge Funds Weigh In On ProQR Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Axiom Investment Management LLC purchased a new position in ProQR Therapeutics during the first quarter worth approximately $53,000. RFG Advisory LLC boosted its holdings in shares of ProQR Therapeutics by 236.8% in the 2nd quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company's stock valued at $119,000 after purchasing an additional 45,000 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of ProQR Therapeutics by 6.4% in the 1st quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company's stock valued at $300,000 after purchasing an additional 11,186 shares during the last quarter. Finally, Walleye Capital LLC grew its stake in shares of ProQR Therapeutics by 2.7% during the 1st quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company's stock valued at $984,000 after buying an additional 15,744 shares during the period. Institutional investors and hedge funds own 32.65% of the company's stock.

ProQR Therapeutics Stock Down 9.7%

Shares of ProQR Therapeutics stock opened at $1.31 on Friday. ProQR Therapeutics has a fifty-two week low of $1.30 and a fifty-two week high of $3.10. The firm has a market cap of $138.02 million, a PE ratio of -2.85 and a beta of 0.20. The business's fifty day moving average is $1.89 and its two-hundred day moving average is $1.75.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.04. ProQR Therapeutics had a negative return on equity of 73.83% and a negative net margin of 223.51%. The business had revenue of $10.00 million for the quarter, compared to analysts' expectations of $4.56 million. Equities research analysts anticipate that ProQR Therapeutics will post -0.45 EPS for the current year.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA-based medicines for genetic diseases. The company's research is centered on using RNA therapies to correct or modify disease-causing genetic information, with the goal of addressing conditions that may not be effectively treated through conventional drug-development approaches.

ProQR's technology portfolio includes Axiomer, an RNA-editing platform designed to make precise changes to RNA inside cells. The company has also developed investigational therapies for inherited retinal diseases and other genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.